ANA AMELIA FIALHO DE OLIVEIRA HOFF
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
7 resultados
Resultados de Busca
Agora exibindo 1 - 7 de 7
conferenceObject Cabozantinib versus placebo in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who progressed after prior VEGFR-targeted therapy: Outcomes in prespecified subgroups based on histology subtypes.(2022) CAPDEVILA, Jaume; ROBINSON, Bruce; SHERMAN, Steven I.; JARZAB, Barbara; LIN, Chia-Chi; VAISMAN, Fernanda; HOFF, Ana; HITRE, Erika; BOWLES, Daniel W.; WILLIAMSON, Denise; OLIVER, Jennifer Wright; KEAM, Bhumsuk; BROSE, Marcia S.- Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Results from the phase 3 COSMIC-311 trial.(2021) BROSE, Marcia S.; ROBINSON, Bruce; SHERMAN, Steven I.; JARZAB, Barbara; LIN, Chia-Chi; VAISMAN, Fernanda; HOFF, Ana; HITRE, Erika; BOWLES, Daniel W.; FAORO, Leonardo; BANERJEE, Kamalika; OLIVER, Jennifer; KEAM, Bhumsuk; CAPDEVILA, Jaume
conferenceObject Effect of age and lenvatinib treatment on overall survival for patients with I-131-refractory differentiated thyroid cancer in SELECT(2015) BROSE, Marcia S.; SCHLUMBERGER, Martin; TAHARA, Makoto; WIRTH, Lori J.; ROBINSON, Bruce; ELISEI, Rossella; NEWBOLD, Kate; KIYOTA, Naomi; HOFF, Ana O.; DUTCUS, Corina; SONG, James; SHERMAN, Steven I.; TAYLOR, Matthew HiramconferenceObject Cabozantinib (C) versus placebo (P) in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-targeted therapy: Outcomes in prespecified subgroups based on prior VEGFR-targeted therapy.(2022) HERNANDO, Jorge; CAPDEVILA, Jaume; ROBINSON, Bruce; SHERMAN, Steven I.; JARZAB, Barbara; LIN, Chia-Chi; VAISMAN, Fernanda; HOFF, Ana; HITRE, Erika; BOWLES, Daniel W.; SEN, Suvajit; OLIVER, Jennifer Wright; KEAM, Bhumsuk; BROSE, Marcia S.conferenceObject Efficacy and safety of lenvatinib for the treatment of patients with I-131-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy.(2015) NEWBOLD, Kate; ELISEI, Rossella; TAYLOR, Matthew Hiram; KRZYZANOWSKA, Monika K.; SHAH, Manisha H.; HOFF, Ana O.; ROBINSON, Bruce; DUTCUS, Corina; SONG, James; HABRA, Mouhammed AmirconferenceObject A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with I-134-refractory differentiated thyroid cancer (SELECT)(2014) SCHLUMBERGER, Martin; TAHARA, Makoto; WIRTH, Lori J.; ROBINSON, Bruce; BROSE, Marcia S.; ELLSEL, Rossella; DUTCUS, Corina E.; HARES, Begona de las; ZHU, Junming; HABRA, Mouhamed Amir; NEWBOLD, Kate; SHAH, Manisha H.; HOFF, Ana O.; GIANOUKAKIS, Andrew G.; KIYOTA, Naomi; TAYLOR, Matthew Hiram; KIM, Sung-Bae; KRZYRANOWSKA, Monika K.; SHERMAN, Steven I.conferenceObject A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with I-131-refractory differentiated thyroid cancer (SELECT)(2014) SCHLUMBERGER, Martin; TAHARA, Makoto; WIRTH, Lori J.; ROBINSON, Bruce; BROSE, Marcia S.; ELISEI, Rossella; DUTCUS, Corina E.; HERAS, Begoria de las; ZHU, Junming; HABRA, Mouhammed Amir; NEWBOLD, Kate; SHAH, Manisha H.; HOFF, Ana O.; GIANOUKAKIS, Andrew G.; KIYOTA, Naomi; TAYLOR, Matthew Hiram; KIM, Sung-Bae; KRZYZANOWSKA, Monika K.; SHERMAN, Steven I.